Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Swiss Cancer Institute (SAKK) collaboration for INVINCIBLE-4
Indications
soft tissue sarcoma(Phase 3)
triple-negative breast cancer(Phase 2)
Catalysts
— Q3 2026
Status note INVINCIBLE-3 Phase 3 paused March 2025 due to funding constraints; limited US enrollment resumption planned Q3 2026; INVINCIBLE-4 Phase 2 enrollment resumed March 2026 after protocol amendment; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.